Human monoclonal IgM antibodies with apoptotic activity isolated from cancer patients

Human Antibodies

Volumn 11, Issue 4, 2002, Pages 107-119

  Bändlein, Stephanie ^a   Lorenz, Judith ^a   Ruoff, Nele ^a   Hensel, Frank ^a   Beyer, Ines ^a   Müller, Justus ^a   Neukam, Konrad ^b   Illert, Bertram ^b   Eck, Matthias ^a   Müller Hermelink, Hans Konrad ^a   Vollmers, H Peter ^a,c  

^a Institute of Pathology   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Germ line encoded IgMs; Human monoclonal antibodies; Hybridoma technology; Induction of apoptosis; Natural immunity; Rumor reactivity

Indexed keywords

CANCER ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CM 1; MONOCLONAL ANTIBODY CM 2; MONOCLONAL ANTIBODY LM 1; MONOCLONAL ANTIBODY PM 1; MONOCLONAL ANTIBODY PM 2; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY ENGINEERING; ANTIBODY ISOLATION; APOPTOSIS; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG ACTIVITY; HUMAN; HUMAN CELL; HYBRIDOMA; IN VITRO STUDY; LUNG ADENOCARCINOMA; MALE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL;

EID: 0242684711     PISSN: 10932607     EISSN: None     Source Type: Journal    
DOI: 10.3233/hab-2002-11401     Document Type: Article

References (54)

1. H.R. Hoogenboom and P. Chames, Natural and designer binding sites made by phage display technology, Immunol. Today 21 (2000), 371-378.
2. K.D. Wittrup, Phage on display, Trends Biotechnol 17 (1999), 423-424.
3. M. Little, M. Welschof, M. Braunagel, L. Hermes, C. Christ, A. Keller, P. Rohrbach, T. Kurschner, S. Schmidt, C. Kleist and P. Terness, Generation of a large complex antibody library from multiple donors, J. Immunol. Methods 231 (1999), 3-9.
4. E. Boel, S. Verlaan, M.J. Poppelier, N.A. Westerdaal, J.A. Van Strijp and T. Logtenberg, Functional human monoclonal antibodies of all isotypes constructed from phage display library-derived single-chain Fv antibody fragments, J. Immunol. Methods 239 (2000), 153-166.
5. M. Neuberger and M. Bruggemann, Monoclonal antibodies, Mice perform a human repertoire, Nature 386 (1997), 25-26.
6. C.G. Davis, M.L. Gallo and J.R. Corvalan, Transgenic mice as a source of fully human antibodies for the treatment of cancer, Cancer Metastasis Rev. 18 (1999), 421-425.
7. L.L. Green, Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies, J. Immunol. Methods 231 (1999), 11-23.
8. M.C. Glassy, Production methods for generating human monoclonal antibodies, Hum. Antibodies Hybridomas 4 (1993) 154-165.
9. H.R. Chang, K. Koda, S. Chang and S. Baird, AgSK1, a novel carcinoma associated antigen, Cancer Res. 53 (1993), 1122-1127.
10. K. Koda, M.C. Glassy, M.E. McKnight, J. Yasutomi, N. Saito, M. Dan and N. Nakajima, Immunotherapy for recurrent colorectal cancers with human monoclonal antibody SK-1, Anticancer Res. 21 (2001), 621-627.
11. H.P. Vollmers, R. O'Connor, J. Müller, T. Kirchner, and H.K. Müller-Hermelink, SC-1, a functional human monoclonal antibody against autologous stomach carcinoma cells, Cancer Res. 49 (1989), 2471-2476.
12. H.P. Vollmers, J. Dämmrich, H. Ribbert, S. Grassel, S. Debus, J. Heesemannn, and H.K. Müller-Hermelink, Human monoclonal antibodies from stomach carcinoma patients react with Helicobacter pylori and stimulate stomach cancer cells in vitro, Cancer 74 (1994), 1525-1532.
13. H.P. Vollmers, E. Wozniak, E. Stepien-B?tsch, U. Zimmermann and H.K. Muller Hermelink, A rapid method for purification of monoclonal human IgM from mass culture Hum, Antibodies Hybridomas 7 (1996), 37-41.
14. F. Hensel, R. Hermann, C. Schubert, N. Abé, K. Schmidt, A. Franke, A. Shevchenko, M. Mann, H.K. Müller-Hermelink and H.P. Vollmers, Characterisation of glycosylphosphatidylinositol-linked molecule CD55/Decay-accelerating factor as the receptor for antibody SC-1-induced apoptosis, Cancer Res. 59 (1999), 5299-5306.
15. F. Hensel, S. Brandlein, M. Eck, K. Schmidt, V. Krenn, A. Kloetzer, A. Bachi, M. Mann, H.K. Muller-Hermelink and H.P. Vollmers, A novel proliferation-associated variant of CFR-1 defined by a human monoclonal antibody, Lab. Invest. 81 (2001), 1097-1108.
16. X.D. Yang, X.C. Jia, J.R. Corvalan, P. Wang and C.G. Davis, Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy, Crit. Rev. Oncol. Hematol. 38 (2001), 17-23.
17. D.H. Lynch and X.D. Yang, Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment, Semin. Oncol. 29 (2002), 47-50.
18. R.S. Herbst and D.M. Shin, Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy, Cancer 94 (2002), 1593-1611.
19. M. Pfaff, R. O'Connor, H.P. Vollmers and H.K. Muller-Hermelink, Human monoclonal antibody against a tissue polypeptide antigen-related protein from a patient with a signet-ring cell carcinoma of the stomach, Cancer Res. 50 (1990), 5192-5198.
20. H.P. Vollmers, J. Dämmrich, H. Ribbert, E. Wozniak, and H.K. Müller-Hermelink, Apoptosis of stomach carcinoma cells induced by a human monoclonal antibody, Cancer 76 (1995), 550-558.
21. H.P. Vollmers, F. Hensel, R. Hermann, J. Dämmrich, E. Wozniak, P. Gessner, B. Herrmann, U. Zimmermann and H.K. Müller-Hermelink, Tumor-specific apoptosis by the human monoclonal antibody SC-1: A new therapeutical approach for stomach cancer, Oncology Reports 5 (1998), 35-40.
22. F. Hensel, R. Hermann, S. Brandlein, V. Krenn, B. Schmausser, S. Geis, H.K. Muller-Hermelink and H.P. Vollmers, Regulation of the New Coexpressed CD55 (Decay-Accelerating Factor) Receptor on Stomach Carcinoma Cells Involved in Antibody SC-1-Induced Apoptosis, Lab. Invest. 81 (2001), 1553-1563.
23. F. Hensel, C. Knörr, R. Hermann, V. Krenn, H.K. Müller-Hermelink and H.P. Vollmers, Mitogenic autoantibodies in Helicobacter pylori-associated stomach cancerogenesis, Int. J. Cancer 81 (1999), 229-235.
24. H.P. Vollmers, J. Dämmrich, F. Hensel, H. Ribbert, A. Meyer-Bahlburg, T. Ufken-Gaul, M. v.Korff and H.K. Ml̈ler-Hermelink, Differential expression of apoptosis receptors on diffuse and intestinal type stomach carcinoma, Cancer 79 (1997), 433-440.
25. H.P. Vollmers, U. Zimmermann, V. Krenn, W. Timmermann, B. Illert, F. Heasel, R. Hermann, A. Thiede, M. Wilhelm, H. Rückle-Lanz, L. Reindl and H.K. Müller-Hermelink, Adjuvant therapy for gastric adenocarcinoma with the apoptosis-inducing human monoclonal antibody SC-1: first clinical and histopathological results, Oncol. Rep. 5 (1998), 549-552.
26. R. Hermann, F. Hensel, E.C. Muller, M. Keppler, M. Souto-Carneiro, S. Brandlein, H.K. Muller-Hermelink and H.P. Vollmers, Deactivation of regulatory proteins hnRNP A1 and A2 during SC-1 induced apoptosis, Hum. Antibodies 10 (2001), 83-90.
27. L.W. Burrus, M.E. Zuber, B.A. Lueddecke and B.B. Olwin, Identification of a cysteine-rich receptor for fibroblast growth factors, Mol. Cell Biol., 12 (1992), 5600-5609.
28. J.O. Gonatas, S.G. Mezitis, A. Stieber, B. Fleischer, and N.K. Gonatas, MG-160. A novel sialoglycoprotein of the medial cisternae of the Golgi apparatus, J. Biol. Chem., 264 (1989), 646-653.
29. A. Stieber, Z. Mourelatos, Y.J. Chen, N. Le Douarin, and N.K. Gonatas, MG150, a membrane protein of the Golgi apparatus which is homologous to a fibroblast growth factor receptor and to a ligand for E-selectin, is found only in the Golgi apparatus and appears early in chicken embryo development, Exp. Cell Res. 219 (1995), 562-570.
30. M.E. Zuber, Z. Zhou, L.W. Burros and B.B. Olwin, Cysteine-rich FGF receptor regulates intracellular FGF-1 and FGF- 2 levels, J. Cell Physiol. 170 (1997), 217-227.
31. J.O. Gonatas, Y.J. Chen, A. Stieber, Z. Mourelatos, N.K. and Gonatas, Truncations of the c-terminal cytoplasmatic domain of MG160, a medial Golgi sialoprotein, result in its partial transport to the plasma membrane and filopodia, J. Cell Sci. 111 (1998), 249-260.
32. T. Crnogorac-Jurcevic, E. Efthimiou, P. Capelli, E. Blaveri, A. Baron, B. Terris, M. Jones, K. Tyson, C. Bassi, A. Scarpa and N.R. Lemoine, Gene expression profiles of pancreatic cancer and stromal desmoplasia, Oncogene 20 (2001), 7437-7446.
33. M. Steegmaier, A. Levinovitz, S. Isenmann, E. Borges, M. Lentner, H.P. Kocher, B. Kleuser and D. Vestweber, The E-selectin-ligand ESL-1 is a variant of a receptor for fibroblast growth factor, Nature 373 (1995), 615-620.
34. M. Steegmaier, E. Borges, J. Berger, H. Schwarz and D. Vestweber, The E-selectin-ligand ESL-1 is located in the Golgi as well as on microvilli on the cell surface, J. Cell Sci. 110 (1997), 687-694.
35. J. Carmichael, W.D. DeGraff, A.F. Gazdar, J.D. Minna, and J.B. Mitchell, Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing, Cancer Res. 47 (1987), 936-942.
36. H.P. Vollmers, R. O'Connor, J. Müller, T. Kirchner, and H.K. Müller-Hermelink, SC-1, a functional human monoclonal antibody against autologous stomach carcinoma cells, Cancer Res. 49 (1989), 2471-2476.
37. V. Krenn, A. König, F. Hensel, C. Berek, M.M. Souto-Carneiro, W. Haedicke, Y. Wang, H.P. Vollmers and H.-K. Müller-Hermelink, Molecular analysis of rheumatoid factor (RF)-negative B cell hybridomas from rheumatoid synovial tissue: evidence for an antigen-induced stimulation with selection of high mutated IgVH and low mutated IgVL/lambda genes, Clin. Exp. Immunol. 115 (1999), 168-175.
38. F. Hensel, C. Knörr, R. Hermann, V. Krenn, H.K. Müller-Hermelink and H.P. Vollmers, Mitogenic autoantibodies in Helicobacter pylori-associated stomach cancerogenesis, Int. J. Cancer 81 (1999), 229-235.
39. P. Carter, Improving the efficacy of antibody-based cancer therapies, Nature Rev. Cancer 1 (2001), 118-129.
40. L.M. Weiner, An overview of monoclonal antibody therapy of cancer, Semin. Oncol. 26 (1999), 41-50.
41. M. von Mehren and L.M. Weiner, Monoclonal antibody-based therapy, Curr. Opin. Oncol. 8 (1996), 493-498.
42. F.C. Breedveld, Therapeutic monoclonal antibodies, Lancet 355 (2000), 735-740.
43. M.J. Glennie and P.W. Johnson, Clinical trials of antibody therapy, Immunol. Today 21 (2000), 403-410.
44. A.N. Houghton and D.A. Scheinberg, Monoclonal antibody therapies-a 'constant' threat to cancer, Nat. Med. 6 (2000), 373-374.
45. E. Drewe and R.J. Powell, Clinically useful monoclonal antibodies in treatment, J. Clin. Pathol. 55 (2002), 81-85.
46. B. Leyland-Jones, Trastuzumab: hopes and realities, Lancet Oncol. 3 (2002), 137-144.
47. J. Baselga, The EGFR as a target for anticancer therapy-focus on cetuximab, Eur. J. Cancer 37(4) (2001), 16-22.
48. A. Ullrich, L. Coussens, J.S. Hayflick, T.J. Dull, A. Gray, A.W. Tam, J. Lee, Y. Yarden, T.A. Libermann, J. Schlessinger et al., Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells, Nature 309 (1984), 418-425.
49. J.S. de Bono and E.K. Rowinsky, The ErbB receptor family: a therapeutic target for cancer, Trends Mol. Med. 8 (2002), 19-26.
50. R.T. Curnow, Clinical experience with CD64-directed immunotherapy. An overview, Cancer Immunol. Immunother. 45 (1997), 210-215.
51. A.A. Noujaim, B.C. Schultes, R.P. Baum and R. Madiyalakan, Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13-evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo, Cancer Biother, Radiopharm. 16 (2001), 187-203.
52. R.C. Bast, M. Jr, Feeney, H. Lazarus, L.M. Nadler, R.B. Colvin and R.C. Knapp, Reactivity of a monoclonal antibody with human ovarian carcinoma, J. Clin. Invest. 68 (1981); 1331-1337.
53. P.A. Canney, M. Moore, P.M. Wilkinson and R.D. James, Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker, Br J Cancer 50 (1984), 765-769.
54. W. Timmermann, H.P. Vollmers, B. Illert, F. Hensel, M. Eck, A. Tiede, H.K. Ml̈ler-Hermelink, Clinical study with human antibody SC-1: Five year follow up, in preparation, 2002.